Alzheimer's Disease Center (ADC) Program Registry This study is funded with a grant from the National Institute of Health (NIH). This study is enrolling adults aged 60 and older without memory problems, or any age with memory problems, to participate in our ADC program registry. Adults will receive a series of three visits, including memory assessments, cognitive testing, lab draws, and physical function testing. These visits will be conducted on an annual basis. All subjects are asked to bring a study partner to the first visit.
Measuring Physical Activity in Adults with and without Alzheimer's (MPA) The purpose of the study is to understand the types and amounts of physical activities older adults do in their everyday life. This is a 1 week study in which participants wear a small electronic monitor that measures the amount of activity they do throughout the day. Participants or study partners will keep a diary of the participant's daily activities. At the end of the study, participants and their caregivers will be compensated up to $100 for their participation.
Alzheimer's Disease Ketogenic Diet Retention and Feasibility Trial (KDRAFT) The purpose of this study is to evaluate if patients with Alzheimer's disease can stay on a very low carbohydrate (ketogenic) diet and if this diet is beneficial in Alzheimer's disease. The study duration is 4 months where participants will consume a ketogenic diet for 3 months. Study procedures include blood draws, cognitive testing, DEXA scans, MRI's and questionnaires. Participants will be compensated a total of $125 upon study completion. All participants are required to have a study partner for participation in this research study. Funding for this study is provided by a grant from Frontiers Pilot and Collaborative Studies Funding Program and the University of Kansas Alzheimer's Disease Center Pilot Program.
Therapeutic Effects of Intranasally-administered Insulin (INI) in Adults with Amnestic Mild Cognitive Impairment (aMCI) or Mild Alzheimer's Disease (SNIFF) This study is enrolling participants who have mild Alzheimer's Disease (AD) or mild cognitive impairment (MCI) due to AD in a trial to determine if cognitive functioning can be improved after treatment with insulin, administered at home with an intranasal inhaler. Study procedures include MRI's, pen and paper thinking tests, interviews/questionnaires, blood draws for lab tests, physical and neurological exams, ECG's, and lumbar punctures. Those who qualify will be randomized to receive insulin or placebo for 12 months, followed by a 6 month open label period in which all participants will receive insulin. Participants will attend 8 study visits over the course of 18 months and will be compensated $25 for each visit completed, with an additional $100 for each of the 2 lumbar puncture procedures
MK 8931-017 (EPOCH) This study is evaluating the safety and efficacy of a study medication for treatment of Alzheimer's Disease. Participants in this study will take an oral medication once daily for 18 months and come to the clinic for approximately 10 visits throughout the study. Study procedures include MRI's, ophthalmology exams, ECG's, pen and paper thinking tests, blood draws for lab tests, and questionnaires/interviews. Participants will be compensated $100 and their study partners will be compensated $50 for each study visit completed. This study is sponsored by Merck Sharp & Dohme Corp.
Expedition 3 (LZAX) This 18 month international study, sponsored by Eli Lilly and Company, will enroll subjects between the ages of 55 and 90 who have early Alzheimer's disease. Participants will receive monthly infusions of an investigational drug. Other study procedures include: cognitive and physical assessments, MRI scans, a PET scan, laboratory sampling, ECGs, and questionnaires. Participant and caregiver/study-partner will each receive $50 for each study visit completed, with an additional $25 each for meals and travel for certain visits, for a total of $1225 each for the participant and study partner.
TCAD TCAD is a clinical study designed to evaluate whether the investigational drug T-817MA, a neuroprotective agent, has the potential to slow decline in memory and daily functioning in people with Alzheimer's disease. The study will enroll those with mild-to-moderate AD who are 55-85 years old. Participants in this study must have been taking donepezil (Aricept®) for at least 6 months prior to enrollment and will be asked to remain on donepezil throughout the study. Study procedures include questionnaires, pen and paper thinking tests, blood draws, ECG's, physical exams, and MRI's (a CT scan may be substituted if participants are not able to have MRI's due to pacemakers or other reasons). Compensation of $25 is provided for each study visit completed, for a total of $300 for completing all study visits.
Alzheimer's Prevention Program (APP) This new study is a comprehensive research effort to examine strategies to improve health and reduce your risk for chronic diseases, including Alzheimer's disease. We are now enrolling participants 65 years and older without Alzheimer's or dementia for the Alzheimer's Prevention Program (APP). One of the goals of the APP is to learn about potential risk factors and what protective behaviors can effectively reduce the risk of developing Alzheimer's disease. The program focuses on how exercise and nutrition influence healthy and unhealthy aging. Study subjects will receive a risk assessment with an amyloid PET scan, general health screen, healthy lifestyle prescription, and surveillance examinations at follow ups.
Effect of Aerobic Exercise on Alzheimer's Pathophysiology in Preclinical AD (APEX) This study will examine the effects of aerobic exercise in individuals at high risk for Alzheimer's Disease, as determined by an amyloid brain imaging scan. Participants must be age 65 or older, have normal cognition, be physically underactive/sedentary, and be identified at screening with brain imaging tests to have the protein called amyloid. Those who qualify will be randomized to either an aerobic exercise group or a control group. This study will observe whether 52 weeks of aerobic exercise will be associated with lower amyloid levels in the brain, as measured by imaging tests.
Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A-4) This is a study for older individuals who may be at risk for developing memory loss due to Alzheimer's disease (AD), but who do not currently have symptoms of AD. The A4 study is examining an investigational medicine, Solanezumab, which may reduce the impact of a protein known as "amyloid" forming plaques in the brain. Scientists believe that accumulation of amyloid in the brain may play a key role in the eventual development of Alzheimer's disease (AD) -related memory loss. This investigational medicine targets amyloid build-up in the brain with the aim of slowing memory loss associated with the development of AD. Participants in this study must be ages 65-85 with normal thinking and memory function but with evidence of amyloid plaque buildup in the brain, as determined by a PET brain imaging test. Study procedures include PET brain imaging, MRI brain imaging, ECG's, blood draws for lab work, physical and neurological exams, memory and thinking tests, and questionnaires/interviews. A lumbar puncture procedure is optional. Compensation for each study visit completed will be provided.
Insulin For Memory (INFORM) is a study to characterize the relationship between insulin sensitivity and memory. This study will consist of a one-time, 5-6 hour visit to measure insulin sensitivity using a procedure called a hyperinsulinemic clamp. Insulin in the body will be increased to approximate levels that are experienced following a meal, and short memory tests will be given prior to and during increased insulin. Glucose will be administered along with insulin to maintain normal blood glucose levels. Compensation for participation is $75. To participate in this study, individuals must be part or be willing to enroll in the ADC Registry.
ASPirin in Reducing Events in the Elderly (ASPREE) This study is sponsored through the National Institute on Aging. The study is currently enrolling participants with no memory problems in the following age groups: African Americans and Hispanics age 65+, other Minorities age 70+ and Caucasians age 75 and older. The study seeks to understand how low doses of aspirin may help promote healthy aging and may help to prevent Alzheimer's disease. Study subjects will complete two screening visits during the first year of the program, and attend annual study visits for a period of five years. Participants will be compensated $50 for completion of visit 1 and 2, and $100 for completion of each annual visit, for a total of $600 if you complete the study.